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Abstract
Background: The frequency of canine heartworm infection in the state of Rio de Janeiro, Brazil was high before
chemoprophylactic treatment was available, with one of the highest rates of infection (52.5 %) found among dogs
living on the eastern shore of the state. Following the launch of a chemoprophylactic product, the rate of infection
gradually decreased, and new infections were rarely reported. After 2005, outbreaks reported at the eastern shore
as well as for new infections in other areas of high infection frequency were considered to possibly be related to
reduced efficacy of macrocyclic lactones. Therefore, this study aimed to evaluate the efficacy of topical heartworm
preventatives from different drug families at the high challenge area of the state of Rio de Janeiro.
Methods: A total of 46 dogs, including animals negative for Dirofilaria immitis microfilariae and antigen (Snap 4 Dx,
IDEXX Laboratories, USA) at the initial screening were randomly allocated to two monthly treatment groups. Dogs
in one group received topical moxidectin + imidacloprid and dogs in the other group received topical selamectin
for eight consecutive months. Blood samples were obtained for microfilariae and antigen detection until the
eleventh month after the first treatment. Dogs becoming microfilaremic or antigenemic on or before day 180 were
considered to be infected prior to the first dose and were excluded from the study.
Results: A total of 29 dogs completed the study, including 14 treated with moxidectin + imidacloprid and 15
treated with selamectin. No dogs treated with moxidectin + imidacloprid (0/14) became infected during the
treatment period, whereas four dogs of the selamectin group (4/15) became infected.
Conclusion: Topical moxidectin + imidacloprid is 100 % effective in preventing D. immitis infections in dogs living
in a high challenge natural environment.
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Background
Dirofilaria immitis (Leidy, 1856) Raillet & Henry, 1911
is a mosquito-borne parasite species present worldwide
and is frequently found infecting Brazilian dogs [1]. As
in other areas of the world, its transmission depends on
the presence of microfilaremic dogs, competent mos-
quito vectors, and susceptible dogs [2, 3].
Before the year of 1992, when the first chemoprophy-
lactic treatment was launched in Brazil, reported canine
heartworm infection frequency at the state of Rio de
Janeiro ranged from 14 % to 17 % [4, 5]. During those
years (1988–1990), at the eastern shore of the state, the
frequency was as high as 52.5 % [5]. During the follow-
ing years (2000–2001), after the first chemoprophylactic
product was launched, a downward trend in heartworm
infection occurred in Brazil [6, 7], and new infections
were rarely reported.
In 2005, following the availability of chemopro-
phylactic heartworm treatments, the first heartworm
outbreak in the state was identified in the area of the
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eastern shore, with 53 % of the dogs found to be in-
fected [8]. Following the first outbreak, many other
infections were reported, and lack of efficacy of
macrocyclic lactones in preventing infections was sus-
pected in high infection frequency areas of the state
[9]. An update of the 2005 outbreak area six years
later showed that infection frequency was even higher
(80 %) [10, 11], which, along with local veterinarians
reports that dogs on chemoprophylaxis were becom-
ing infected (personal communication), suggests the
presence of less susceptible populations of D. immitis
at the site. Therefore, the aim of this study was to
evaluate the efficacy of topical heartworm preventa-
tives from different drug families at the high chal-
lenge area of the state of Rio de Janeiro.
Methods
In order to identify as many as possible D. immitis
microfilariae and antigen negative dogs living at the
high challenge area, all dog owners were invited to
participate of the study. According to the approval of
the ethical committee of the Universidade Federal
Fluminense (233) and after obtaining owner consent,
blood samples were obtained from 80 chemoprophy-
laxis naïve dogs (32 under 12 months old; 19 from 1
to 2 years old and 29 over 2 years) for detection of
microfilariae using Knott´s modified test (Newton &
Wright, 1956) and ELISA test (Snap 4 Dx IDEXX
Laboratories, USA).
After screening, 46 out of the 49 dogs with negative
test results on both tests (26/46, 56.5 % less than 1 year
of age) were included in the study and randomly sorted
in two groups; dogs in one group received topical moxi-
dectin + imidacloprid at 2.5 to 6.25 mg moxidectin/kg/
month (23 dogs); dogs in the second group received
topical selamectin at 6 to 12 mg/kg/month (23 dogs).
Every monthly treatment was administered by the
veterinarians participating in the study after weighing
the dogs and adjusting the dose if necessary. Dogs were
treated on days 0, 30, 60, 90, 120, 150, 180 and 210
(±5 days), and blood samples were obtained on days −2,
30, 90, 150, 180, 210, 240, 270, and 300 (±5 days) for
microfilariae detection. On days −2, 90, 150, 180, and 300,
plasma samples were tested for detection of antigens by
the same ELISA test used for the initial screening. Plasma
from all microfilaremic samples obtained on days 30, 210,
240, or 270 was also tested for antigens (Fig. 1).
Dogs becoming microfilaremic or antigenemic on day
180 or before were considered to be infected prior to the
first chemoprophylactic dose. Those dogs and any other
inadvertently treated with macrocyclic lactones by the
owners were excluded from the study.
Detection of infected dogs during the study were eval-
uated for significance of differences between the treat-
ment groups by chi square or Fisher’s exact tests.
Results
The initial screening of 80 dogs detected 31 positive
for microfilariae and/or D. immitis antigen (38.8 %).
Among the 46 dogs included, 14 of the moxidectin +
imidacloprid group and 15 of the selamectin group
completed the study. On day 180, one of the selamec-
tin dogs became microfilaremic and became antigen
positive later. Therefore, this dog was considered to
have been previously infected before the study was
initiated. The number of dogs in the selamectin group
that became infected during the treatment period (4/15)
was higher than the moxidectin + imidacloprid treated
group (0/14) (χ2 = 2.38; p = 0.057) (Table 1). Among the
four selamectin-treated dogs that became infected during
the study, three tested positive for microfilariae and anti-
gen and one was antigen-positive but was amicrofilaremic.
Therefore the efficacy of the selamectin treatment was
73.3 % and the efficacy of the moxidectin + imidacloprid
treatment was 100 %.
Discussion
Because dogs had to be free of detectable microfilariae
and antigens to be included in the study and the chal-
lenge at the study site was known as very high, young
Fig. 1 Timeline of canine treatments and blood sampling.
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dogs were privileged. Even so, the percent of positive test
results was high (38.75 %), confirming previous results
[11] and demonstrating how intense the challenge was.
Therefore, the severe life threatening cardiopulmonary
condition the infection determines, the risk treatment
imposes to the dogs and the zoonotic potential of the in-
fection highlights the definite need for chemoprophy-
laxis in order to control transmission. Minimizing the
number of infected dogs acting as reservoirs of the para-
site is pivotal to reduce the chance of infective blood
meals for mosquitoes and to reduce the occurrence of
D. immitis in vectors, dogs and humans. Besides the dir-
ect impact upon D. immitis transmission, the use of top-
ical moxidectin/imidacloprid or topical selamectin
provides reliable control against other major endo and
ectoparasites.
The main reasons for macrocyclic lactones treatment
failures which may impair analysis of lack of efficacy or
resistance are known to be underdosing and owners’
noncompliance [12–15], which were carefully con-
trolled in the present study. Therefore, the results ob-
tained ruled out major indirect reasons for lack of
efficacy at a high natural challenge area were the occur-
rence of resistant populations or lack of efficacy can´t
be disregarded.
Topical moxidectin + imidacloprid was more effica-
cious (100 %) than topical selamectin (73.3 %) in pre-
venting D. immitis infection, as it had been shown
before when the resistant strains MP3 or JYD-34 were
used as models for evaluation of efficacy [13, 16, 17].
Furthermore, it should be considered that since macro-
cyclic lactones may stunt D. immitis development for
nine months when administered accordingly to recom-
mendations (John Wilson McCall - personal communi-
cation), it is possible to assume that infection of the
selamectin dogs occurred prior to the first treatment
dose and that selamectin treatment was ineffective in
eliminating the infection although stunted worm
development.
Therefore, it is possible to infer that topical moxidec-
tin + imidacloprid, when consistently administered to
dogs on a monthly schedule, is highly effective in pre-
venting heartworm patent infections in treated dogs
living in extreme challenge situations, such as those
found in the coastal lowland of the eastern state of Rio
de Janeiro, Brazil [8, 9, 11, 18], the Mississippi delta in
the United States [12], and others.
Conclusions
Topical moxidectin + imidacloprid was 100 % effect-
ive for D. immitis prevention in dogs living in a high
challenge natural environment therefore at those
environments should be the chemoprophylaxis of
choice. These results suggest that experimental stud-
ies should be conducted to elucidate the stunting
effect of different macrocyclic lactones consistent
treatment.
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